UK access to PrEP ‘indefinitely postponed’ due to Covid-19
The NHS rollout of the HIV-preventing drug regimen PrEP (pre-exposure prophylaxis) has been...
Focus:
-
![]()
CDC identifies significant racial disparity among newly diagnosed cases of HIV
-
![]()
Novartis’ Cosentyx outperforms Humira in PsA-specific endpoints
-
Pandion and Astellas sign deal for Type 1 diabetes bispecifics
-
![Janssen Stelara UC]()
FDA approves Janssen’s Stelara for adults with UC
-
![EC Stelara ulcerative colitis]()
EC expands label of Janssen’s Stelara to include ulcerative colitis
-
![genetics for psoriasis drug development]()
Psoriasis Action Month: using genetics to improve drug development
Most Read
- UK access to PrEP ‘indefinitely postponed’ due to Covid-19
- Novartis’ Cosentyx outperforms Humira in PsA-specific endpoints
- FDA approves Janssen’s Stelara for adults with UC
- EC expands label of Janssen’s Stelara to include ulcerative colitis
- Psoriasis Action Month: using genetics to improve drug development
Latest Content
UK access to PrEP ‘indefinitely postponed’ due to Covid-19
The NHS rollout of the HIV-preventing drug regimen PrEP (pre-exposure prophylaxis) has been ‘indefinitely postponed’ due to the Covid-19 pandemic, according to iNews.
Why are patients struggling to access life-saving immune globulin?
Immune deficient patients across the world are having issues getting access to the only drug that can keep them alive: immune globulin. Allie Nawrat investigates what is behind this ongoing shortage, whether medicine stockpiling is adding fuel to the fire, and what can be done to prevent a repeat of this situation in the future.
Takeda’s SC Entyvio meets primary endpoint in Crohn’s Disease
At the European Crohn’s and Colitis Organization (ECCO) congress in Vienna, Austria, Takeda announced the subcutaneous (SC) formulation of Entyvio (vedolizumab) met its primary endpoint in Crohn’s Disease.
Evidence grows for screening family members of those with celiac disease
There is currently no routine screening of celiac disease in genetically predisposed individuals.
Treatment options for Philadelphia chromosome-positive leukaemia
3D illustration showing defective 9 and 22 chromosomes with translocational defect which causes cause chronic myelogenous leukaemia.
Novartis’ Cosentyx outperforms Humira in PsA-specific endpoints
Novartis has announced its biologic Cosentyx (secukinumab) was superior to AbbVie’s blockbuster Humira (adalimumab) in psoriatic arthritis (PsA) endpoints of the EXCEED head-to-head trial.
Pandion and Astellas sign deal for Type 1 diabetes bispecifics
Pandion Therapeutics and Astellas Pharma have signed a $795m agreement for the research, development and commercialisation of locally acting immunomodulators to treat Type 1 diabetes, as well as other autoimmune diseases of the pancreas.
Latest News
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.
Close
Close
Close
Go Top